Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Autor: Sehmus Ertop, Alperen Kizikli, Rahsan Yildirim, Huseyin Derya Dincyurek, Nilgun Sayinalp, Sinan Demircioğlu, Güray Saydam, Ismet Aydogdu, Abdulkadir Basturk, Erdal Kurtoğlu, Ahmet Seyhanli, Olga Meltem Akay, Hatice Terzi, Burak Deveci, Omer Ozcan, Eren Arslan Davulcu, Güven Çetin, Ali Ünal, Emel Gürkan, Vahap Okan, Elif Gülsüm Ümit, Aydan Akdeniz, Burhan Turgut, Vildan Özkocamaz, Anil Tombak, Derya Selim Batur, Mehmet Sönmez, Ilhami Berber, Burhan Ferhanoglu, Birsen Sahip, Mehmet Ali Ucar, Ahmet Kursad Gunes, Mehmet Yilmaz, Mehmet Ali Özcan, Mehmet Hilmi Dogu, Gül İlhan, Gülsüm Özet, Seval Akpinar, Funda Pepedil Tanrikulu, Demet Çekdemir, Emin Kaya, Özgür Mehtap, Mufide Okay, Irfan Yavasoglu, Salih Sertac Durusoy
Přispěvatelé: ÇETİN, GÜVEN
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
medicine.medical_specialty
Bruton's tyrosine kinase inhibitor
Turkey
Lymphoma
Anemia
Chronic lymphocytic leukemia
Follow-Up
ECOG Performance Status
Neutropenia
Bruton’s tyrosine kinase inhibitor
Trial
chemistry.chemical_compound
Phase-3
Piperidines
Internal medicine
medicine
Humans
Chemoimmunotherapy
Stage (cooking)
Adverse effect
Aged
Retrospective Studies
business.industry
Adenine
Ibrutinib
Hematology
Middle Aged
medicine.disease
Leukemia
Lymphocytic
Chronic
B-Cell
Comorbidity
Fludarabine Plus Cyclophosphamide
Treatment Outcome
chemistry
Retrospective Analysis of Real-Life Data-
TURKISH JOURNAL OF HEMATOLOGY
cilt.38
sa.4
ss.273-285
2021 [TOMBAK A.
Tanrikulu F. P.
Durusoy S. S.
DİNÇYÜREK H. D.
KAYA E.
ÜMİT E. G.
YAVAŞOĞLU İ.
MEHTAP Ö.
Deveci B.
ÖZCAN M. A.
et al.
-Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia]
Female
Open-Label
business
Rituximab
Cll
Research Article
Zdroj: Turkish Journal of Hematology
Popis: Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard deviation: 64.6 +/- 10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p
Janssen Pharmaceutica Turkey
This study was supported by Janssen Pharmaceutica Turkey. The authors would like to thank Prof. Sule Oktay, MD, PhD, and Cala Ayhan, MD, from KAPPA Consultancy Training Research Ltd. (stanbul, Turkey) , who provided editorial support.
Databáze: OpenAIRE
Externí odkaz: